Drugs in MeSH Category Adrenergic beta-1 Receptor Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Able	ATENOLOL	atenolol	TABLET;ORAL	076907-003	Jul 30, 2004		DISCN	No	No
Unichem	ATENOLOL	atenolol	TABLET;ORAL	213136-002	Nov 21, 2019	AB	RX	No	No
Aiping Pharm Inc	ATENOLOL	atenolol	TABLET;ORAL	072304-001	Jul 15, 1988	AB	RX	No	No
Teva Pharms	BISOPROLOL FUMARATE	bisoprolol fumarate	TABLET;ORAL	075644-002	Jun 26, 2001		DISCN	No	No

Market dynamics and patent landscape for NLM MeSH Class: Adrenergic beta-1 Receptor Antagonists

Last updated: July 20, 2026

Beta-1 selective (cardioselective) beta-blockers drive a mature, heavily genericized market with episodic value tied to combination products, new salts/polymorphs, long-acting delivery systems, and limited new clinical-differentiation programs. In the patent landscape, the remaining enforceable rights tend to cluster around (i) extended-release formulations and dosing regimens, (ii) combination products that include diuretics or other cardiovascular agents, and (iii) manufacturing/process claims for specific dosage forms. The core “beta-blocker” scaffold is broadly generic in the US, and many legacy patents have expired or are well past peak enforceability.

At a high level, market dynamics for beta-1 receptor antagonists are shaped by: (1) ongoing substitution to low-cost generics and payor-driven formulary preference, (2) patent thickets for extended-release and fixed-dose combinations, (3) periodic FDA and state-level interchange rules that accelerate switching to the lowest AWP/generic acquisition cost, and (4) litigation that is more common for combination/extended-release products than for immediate-release single agents.

Which beta-1 receptor antagonists dominate the MeSH class and how do they compete on patent life?

Featured-snippet answer: The market concentrates on metoprolol (immediate- and extended-release), atenolol, bisoprolol, and nebivolol, with market premium opportunities concentrated in extended-release formats and fixed-dose combination products.

What drugs are typically grouped under Adrenergic beta-1 Receptor Antagonists?

Commonly marketed beta-1 selective antagonists include:

• Metoprolol (tartrate, succinate ER)
• Atenolol
• Bisoprolol
• Nebivolol
• Betaxolol (ophthalmic use also appears in some classifications, but the systemic class is dominated by the above)

How does the patent clock differ by active ingredient?

• Metoprolol: Legacy single-agent patents are largely expired in most jurisdictions; remaining enforceable rights typically relate to specific ER formulations, combinations, and manufacturing/process changes.
• Atenolol: Predominantly generic; patent life in practice is not a major barrier except for niche reformulations/brand differentiations (where still extant).
• Bisoprolol: Heavily genericized; late-stage protection is more likely tied to dosing form improvements than to primary compound claims.
• Nebivolol: Genericized broadly; residual protection can still appear in certain formulations or combination packs.

Market structure: mature core vs. near-term “last mile” value

Business-relevant division:

• Core immediate-release beta-1 blockers are largely commoditized.
• ER and combination products carry the residual IP leverage.
• Payors and PBMs often drive rapid generic substitution for immediate-release tablets and concentrate spend on fewer SKUs for ER and combination products due to adherence, formulary tiering, and substitution policies.

What patents protect metoprolol, atenolol, bisoprolol, and nebivolol in current practice?

Featured-snippet answer: Remaining patent coverage is usually formulation and process oriented (extended-release matrices, salts, polymorphs, release kinetics, and specific manufacturing steps) rather than new beta-blocker chemotypes.

What is the typical claim set in this MeSH class?

Patent families in this class commonly include:

• Extended-release formulation claims
  • Specific polymers/matrix compositions
  • Particle size ranges or blend parameters
  • Release-rate constraints (pharmacokinetic targets)
  • Bead, pellet, or multilayer tablet architectures
• Combination-product claims
  • Fixed-dose pairings with diuretics or other cardiovascular agents
  • Unit-dose ratios
  • Stability and compatibility claims for combination packs
• Method-of-use claims
  • Specific titration and dosing schedules (more frequent in ER products)
  • Indication-specific regimens, sometimes supporting labeling differentiation
• Manufacturing/process claims
  • Granulation steps, coating parameters, drying conditions
  • Control of critical process parameters that affect dissolution and bioavailability

How many patents cover the MeSH class compounds versus the formulations?

In mature beta-blocker markets, the number of active compound patents per ingredient is low (often fully expired), while the number of active formulation and process patents per ER/combo SKU can be materially higher. Practically, “how many patents” depends on product form and jurisdiction, but the enforceable estate is concentrated on the product-specific dossiers rather than the base molecules.

How strong are these patents for litigation and settlement leverage?

Enforceability tends to hinge on:

• Claim construction breadth (release-profile and composition ranges)
• Objective test support in specification (dissolution method, acceptance criteria)
• Obviousness and enablement positions tied to known ER beta-blocker technologies
• Whether generic entrants can design around via alternative excipients, polymers, or release mechanisms

When does exclusivity end for beta-1 blockers, and what drives the FDA timing for generic entry?

Featured-snippet answer: For most beta-1 blockers, data exclusivity barriers are minimal due to long-standing approval dates and generic substitution. The dominant timing constraint is device/formulation IP and, for challengers, Paragraph IV windows where applicable.

What exclusivity types matter in this class?

• New Chemical Entity (NCE) exclusivity: generally not applicable to these established beta-1 blockers.
• New Clinical Investigation (NCI) exclusivity: can apply only if a sponsor secured a new exclusivity-triggering study for a specific labeling change; it is uncommon for legacy ER relaunches.
• Orange Book exclusivity (non-patent exclusivity): rare in late-life formulation changes unless linked to specific regulatory exclusivity triggers.

How do extended-release reformulations affect the exclusivity and challenge timeline?

ER reformulations can create:

• Additional Orange Book patent listings covering dissolution profiles and compositional features.
• Legal exposure windows tied to those listings rather than to any broad, molecule-level exclusivity.

What drives Paragraph IV opportunities?

Paragraph IV opportunities arise when:

• A generic files an ANDA referencing a listed ER/combo NDA and certifies against one or more Orange Book patents.
• The Orange Book has still-active patent listings for that particular SKU.

In practice, the generics bar is most active where patents cover:

• Specific ER dosage forms
• Fixed-dose combinations
• Manufacturing methods that directly affect dissolution/bioavailability

What is the Orange Book status of beta-1 antagonists and their formulation patents?

Featured-snippet answer: Orange Book coverage is typically concentrated in extended-release formulations and combination products. Immediate-release single agents usually have little to no active patent listings in the modern timeframe.

How Orange Book listings shape market entry

Orange Book listing patterns affect:

• Whether an ANDA applicant must certify against product-specific formulation patents.
• The number of patents asserted in litigation and the settlement “stack” required for launch.

How to interpret listing density for this class

• High listing density correlates with frequent litigation and multi-patent settlements for ER/combo SKUs.
• Low listing density correlates with faster generic entry and reduced settlement complexity.

Which companies challenge beta-1 blocker patents via Paragraph IV, and how does the litigation pattern look?

Featured-snippet answer: Generic challengers typically target ER and combination products where patent estates remain active. Litigation patterns in this class usually resolve through settlements that allow staggered launch dates or carve-outs based on dosage strength, method of manufacture, or formulation design-around.

Typical litigation architecture

Cases commonly involve:

• Multiple Orange Book patents asserted in the complaint.
• Expert-driven disputes over dissolution profiles and equivalence.
• Settlement agreements with launch dates and sometimes covenants not to sue tied to specific generic product characteristics.

What settlement terms dominate?

Market practice for settlements in this class includes:

• Agreed launch date(s) for the generic product strength(s)
• Non-infringement positions for design-around formulations
• Dismissal of claims following payment terms (where present)
• Consent to entry contingent on maintaining specific manufacturing parameters

What formulations are protected: immediate-release vs extended-release beta-1 antagonists?

Featured-snippet answer: Extended-release formulations are the primary source of enforceable IP, with immediate-release products usually offering less patent friction.

What formulation patents commonly protect ER beta-1 blockers?

Protected elements often include:

• Composition of the ER matrix (polymer blend identity and proportions)
• Coating compositions and thickness
• Tablet architecture (layering or pellet-based ER)
• Dissolution method and acceptable dissolution windows
• Bioavailability and release kinetics targets linked to in vivo performance

Why ER is the litigation hotspot

ER generics must match:

• Dissolution and release profile
• Exposure metrics (Cmax and AUC patterns)
• In some cases, in vivo bioequivalence targets that are sensitive to formulation differences

That creates both:

• Higher infringement risk for entrants
• Higher patent settlement leverage for brand holders

How do biosimilar risks apply to this MeSH class?

Featured-snippet answer: Biosimilar risks do not materially apply because adrenergic beta-1 receptor antagonists are small molecules, not biologics.

What is the relevant “follow-on” risk instead?

The primary competitive threat is:

• ANDA generic entry for oral tablets and ER dosage forms
• Design-around reformulation where feasible
• Patent-driven launch delay via litigation and settlement structures

How do beta-1 antagonists compare with other beta-blockers (beta-1 vs nonselective) in patent durability?

Featured-snippet answer: Beta-1 selective antagonists share the same commoditization dynamics as other older beta-blockers; the durability tends to track product form (ER/combo) more than receptor selectivity.

What differs strategically versus nonselective beta-blockers?

Nonselective beta-blockers (for example, propranolol) can share the same patent expiration profile, but competitive positioning can differ based on:

• Specific ER/combo product life cycles
• Differences in market uptake for particular indications
• Regional brand remnants and tender systems

Revenue exposure and generic launch scenarios: what matters for an investor or licensor?

Featured-snippet answer: The highest revenue exposure sits with ER and combination SKUs that still have active Orange Book listings. Immediate-release products have lower litigation-driven delay potential.

What are the dominant generic launch scenarios?

Three market-relevant scenarios:

1. Immediate generic entry upon patent expiry or non-assertion
2. Launch after settlement with delayed entry date and scoped product characteristics
3. Partial launch by strength or subset of formulations if the brand retains enforceable coverage for other SKUs

What metrics drive enterprise value in this class?

• Share of spend tied to ER/combo products
• Tender pricing sensitivity and PBM contracting behavior
• Ongoing litigation schedule (trial dates, appeal posture)
• Product lifecycle management (switching from brand to authorized generics where applicable)

Geographic coverage: where are the patent barriers usually highest?

Featured-snippet answer: For this class, US is often the core litigation arena for ER/combo SKUs due to Orange Book-driven ANDA timing; Europe and key markets tend to mirror formulation IP rather than compound IP.

Where patent enforcement tends to be most material

• United States: strongest link between patent listings and ANDA launch timing
• EU5 and UK: formulation/process patents can still delay launch where national validity and infringement determinations align
• Other markets: often accelerate generic entry unless formulation patents are specifically enforced and kept in force

Key Takeaways

• Beta-1 selective beta-blockers are largely mature and genericized; patent leverage concentrates on extended-release formulations, combinations, and formulation/process claims rather than base molecules.
• Generic entry timing is typically governed by Orange Book patent listings for specific ER/combo SKUs, not by data exclusivity.
• Litigation and settlement structures usually focus on ER and combination products due to dissolution/bioequivalence sensitivity and claim scope around release mechanisms.
• Biosimilar dynamics do not apply; the follow-on threat is ANDA-based small-molecule generic entry and design-around reformulation.

FAQs

1) What patent claim types are most frequently litigated for metoprolol ER?
Extended-release composition and matrix/pellet architectures plus dissolution/release profile constraints, followed by manufacturing/process claims that impact bioequivalence.

2) Do beta-1 blockers have meaningful remaining patent protection for immediate-release tablets?
Typically less than ER and combination products; immediate-release single-agent markets often show limited active Orange Book coverage in the modern timeframe.

3) How do Paragraph IV filings generally cluster for beta-1 receptor antagonists?
They cluster around ER and fixed-dose combination SKUs with active Orange Book listings, creating multi-patent litigation and settlement stacks.

4) What does a “design-around” look like for ER beta-blocker generics?
Alternative polymer blends, coating systems, or ER matrix designs that achieve comparable dissolution and in vivo exposure without practicing the listed formulation/process claims.

5) Are there exclusivity or settlement levers beyond patents for this MeSH class?
Non-patent exclusivity is usually not the primary lever; most timing and commercial outcomes depend on Orange Book-listed patents and settlement agreements tied to launch dates and product characteristics.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs.
3. National Library of Medicine. MeSH (Medical Subject Headings): Adrenergic beta-1 Receptor Antagonists.